04930nam 2201237z- 450 991055714810332120231214133001.0(CKB)5400000000040577(oapen)https://directory.doabooks.org/handle/20.500.12854/68388(EXLCZ)99540000000004057720202105d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierMetabolism and Metabolomics of Liver in Health and DiseaseBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 electronic resource (268 p.)3-03943-635-X 3-03943-636-8 Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.Medicinebicsscnonalcoholic fatty liver diseasenonalcoholic steatohepatitisFibrosisLiver biopsyGenomicsMetabolomicsProteomicsTranscriptomicsnicotinamideNAFLDsteatosisheat stressprimary mouse hepatocytesmetabolic profileGC-MSmultivariate statistical analysisarachidonic aciddocosahexaenoic acidinflammationfibrosislipidomicsmass spectrometryin vitroHepaRGsodium saccharinreference toxicantsde novo lipogenesiscarbohydrate response element-binding proteinChREBPdiabetesglucose productionglycogenglycolysisglycogen storage disease type Ihexosaminepentose phosphate pathwayacupunctureimflammationlipid metabolismoxidative stressmetabolomics quantitative profiling1H-NMR spectroscopyliverbile acidsmetabolomicsrat plasmatandem mass spectrometryliquid chromatographyacetaminophenhepatotoxicitybiomarkerpremalignantalcoholic liver diseasecholestasiscirrhosisNAFLNASHstandard operating proceduresurinebloodfecestissuecellsliver functionnonalcoholic fatty liverliquid chromatography-mass spectrometrynuclear magnetic resonance spectroscopymetabolic pathwaynon-alcoholic fatty liver diseasenon-alcoholic steatohepatitistranscription factorsmetabolic stresslipid homeostasisglucose homeostasisMedicineWahli Walteredt1328658Guillou HervéedtWahli WalterothGuillou HervéothBOOK9910557148103321Metabolism and Metabolomics of Liver in Health and Disease3038789UNINA